VivoSeq
Other

Smoking Cessation

113

Pipeline Programs↗

47

Active Trials↗

39

Companies Involved↗

Smoking Cessation is a highly competitive landscape with 113 programs across 39 companies. The most active players are Embera NeuroTherapeutics, Inc., Merck & Co., Otsuka. 28 therapies are approved with 18 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

74/100

Pipeline Velocity

39/100

Mech. Concentration

8/100

Completion Rate

89/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

E

Embera NeuroTherapeutics, Inc.

1 program

Phase 2Merck & Co. logo

Merck & Co.

1 program

Phase 2Otsuka logo

Otsuka

1 program

Phase 2C

Celtic Pharma Development Services

1 program

Phase 2A

Arena Pharmaceuticals

1 program

Phase 2P

Promius Pharma, LLC

1 program

Phase 2

Pipeline

Programs by Phase

Preclinical17

Nicotine Replacement Patches

Mayo Clinic

Progesterone

Ferring

Psilocybin-Assisted Treatment

Johns Hopkins University

Sibutramine

Abbott

Nicotine Patches

University of California, San Diego

Phase 16

Exenatide

AstraZeneca

Isradipine

Glaxo Dba Glaxosmithkline

Nicotine Pouches

Johns Hopkins University

Mecamylamine

Targacept Inc.

Cycloserine

University of Calgary

Phase 244

Nalmefene

Indivior Inc.

Guanfacine

Promius Pharma, LLC

Gemfibrozil

Pfizer

Simvastatin

Organon and Co

Zonisamide

Azurity Pharmaceuticals

Phase 318

Semaglutide

Novo Nordisk

Rimonabant

Sanofi

Bupropion Hydrochloride

GSK

Varenicline Tartrate

Pfizer

Topiramate

Wim Janssens

Approved28

Nicotine

Pfizer

Varenicline

Prism Pharmaceuticals

Propranolol

Wyeth-Lederle Vaccines

Suvorexant

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Bupropion

Glaxo Dba Glaxosmithkline

Analysis

Modality Breakdown

98%

Small molecule

147 of 150 classified programs — the dominant modality here.

2%ALL OTHERSPeptide32%

Small molecule leads; the ring shows all 150 classified programs, each share of the total. Modality classified for 99% of 155 pipeline programs.

Analysis

Trial Status

342

clinical trials

Completed247 · 72%
Recruiting23 · 7%
Terminated19 · 6%
Unknown status19 · 6%
Active, not recruiting16 · 5%
Withdrawn10 · 3%
Other8 · 2%

Clinical Trials

Trial Activity

342 trials

Smoking Cessation Programme in Workplaces in Hong Kong (Phase ⅤII)
Recruiting·TThe University of Hong Kong·N/A·NCT06932718·328 enrolled
Smoking Cessation Program in the Construction Sector
Recruiting·UUniversity of Miami·Phase 4·NCT06098144·608 enrolled
Study to Evaluate Music Therapy and Nicotine Replacement Therapy on Craving Related to Smoking Cessation in Students
Recruiting·PPoitiers University Hospital·N/A·NCT05589220·120 enrolled
The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers
Recruiting·UUniversity of Athens·N/A·NCT06885970·200 enrolled
Semaglutide for Post-Smoking Cessation Weight Management
Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06173778·197 enrolled
Community-based Smoking Cessation Treatment for Adults With High Stress Sensitivity.
Recruiting·—·Phase 3·NCT06053567·360 enrolled
Leveraging Community Pharmacists to Optimize Smoking Cessation Services for Rural Smokers in Appalachia
Recruiting·UUniversity of Virginia·N/A·NCT05660525·768 enrolled
tDCS Plus Varenicline for Smoking Cessation
Recruiting·CCentre for Addiction and Mental Health·Phase 4·NCT06798324·160 enrolled
Neuroimaging Correlates and Feasibility of Transcranial Magnetic Stimulation (TMS) to Improve Smoking Cessation Outcomes in Veterans With Comorbid PTSD
Recruiting·VVA Office of Research and Development·Phase 2·NCT05723588·50 enrolled
Combination of Acupuncture, Auricular Acupressure and Nicotine Replacement Therapy for Smoking Cessation
Recruiting·TThe University of Hong Kong·N/A·NCT06931054·270 enrolled
Integrating Financial Coaching and Smoking Cessation Coaching
Recruiting·NNYU Langone Health·Phase 3·NCT05154669·488 enrolled
Evaluating Smoking Cessation Interventions for PWH in South Africa
Recruiting·JJohns Hopkins University·Phase 2/3·NCT05413122·660 enrolled
Smoking Cessation With Varenicline in Schizophrenia: Antipsychotic-Induced Neurological Symptoms as Correlates
Recruiting·—·Phase 4·NCT03495024·10 enrolled
Smoking Cessation and Menstrual Cycle Phase
Recruiting·CCentre for Addiction and Mental Health·Phase 4·NCT05515354·1,200 enrolled
Combination Nicotine Replacement Therapy, Cytisine, or Varenicline for Smoking Cessation
Recruiting·OOttawa Heart Institute Research Corporation·Phase 4·NCT06832085·150 enrolled
Page 1 of 23

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)